XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Derivative Instruments - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 31, 2021
Nov. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Derivative, notional amount           $ 600,000,000
Swap termination payments     $ 16,093,000 $ 35,448,000 $ 0  
Derivative collateral received     34,660,000 45,252,000 360,000  
Unrealized gain (loss) on derivatives     (21,532,000) (42,076,000) (39,138,000)  
Other assets     4,145,000 9,997,000    
Interest Rate Swap | Level 1 | Fair Value, Recurring            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Derivative financial instruments     0 5,400,000    
Epizyme Common Stock Warrant            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Warrants to purchase additional shares (in shares)   2,500,000        
Equity Investment In Epizyme Inc.            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Equity securities   $ 100,000,000        
Upfront payment for equity investment   $ 100,000,000        
Equity Investment In Epizyme Inc. | Epizyme Common Stock Warrant            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Exercise price of warrant (in dollars per share)   $ 20        
Term of warrant (in years)   3 years        
Equity Investment In Epizyme Inc. | Put Option            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Put option, term (in months)   18 months        
Put option to sell additional common stock   $ 50,000,000        
Put option, selling price, maximum (in dollars per share)   $ 20        
Treasury Rate Lock Contracts            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Swap termination payments $ 16,100,000          
Interest Rate Swap            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Unrealized gain (loss) on derivatives       (10,900,000) (72,600,000)  
Warrant            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Unrealized gain (loss) on derivatives     $ (5,400,000) $ (25,400,000) 22,000,000  
Forwards | Equity Investment In Epizyme Inc.            
Derivative Instruments and Hedging Activities Disclosures [Line Items]            
Other assets         $ 11,500,000